COLUMBIA, S.C. (November 17, 2022) – Ritedose, a 503B outsourcing facility located in South Carolina, just launched two new unit dose syringe products, Bupivacaine Hydrocholoride 0.25% (2.5 mg/mL) and Bupivacaine Hydrocholoride 0.5% (5 mg/mL). They are ready-to-use drug shortage solutions for hospital pharmacies across the country. Ritedose is a division of The Ritedose Corporation, a 27-year-leader in cGMP drug manufacturing for major pharmaceutical companies and research development programs.
Joining a growing portfolio of 503B single-dose syringe products, both Bupivacaine Hydrocholoride concentrations are preservative free, labeled to meet medication safety standards, have beyond-use-dates of 120 days, and can be stored at room temperature. Sourcing compounded products from a cGMP supplier like Ritedose negates the need for in-hospital compounding and helps decrease the possibility of sub or supra therapeutic doses for patients.
These products hit the market as the U.S. Food & Drug Administration (FDA) reports a national shortage for Bupivacaine Hydrocholoride injections. “We’re pleased to make such a critical supply of Bupivacaine Hydrocholoride available for our hospital partners,” said Ritedose President and CEO Jody Chastain. “Decades of successful cGMP production, extensive development resources and significant, existing manufacturing capacity mean we’re able to swiftly deliver quality medication when the country needs it, so hospitals can avoid disruptions in patient care.”
Founded in 1995 in Columbia, South Carolina, The Ritedose Corporation is an industry leader in the aseptic manufacturing and liquid packaging of drug products and utilizes proven Blow-Fill-Seal (BFS) equipment and processes to ensure efficient, consistent and safe dosage delivery. The company’s 27-year track record includes delivery of more than 8 billion doses since 2012 without interruption, and its current capacity is 2 billion units annually.